Thalys Medical Technology signed a Memorandum of Understanding with iCAN Israel-Cannabis.
According to them, Thalys and iCAN will come together to create a unique partnership to advance the development of early stage incubated companies that focus on the creation of medical technology, agricultural technology and general intellectual property focusing on the medical hemp industry.
"Thalys will help iCAN’s portfolio companies enter the world's most populous consumer market. Thalys, which plans to co-invest in iCAN’s portfolio investments that address Chinese market needs, will have exclusive cooperation rights on iCAN's incubated start-ups and we will have matching stakes in new investments. I am looking forward to working cooperatively with one of China's leading medical technology companies,” said Saul Kaye, CEO of iCAN.
According to the MOU, Thalys will have access to all early stage companies that iCAN is evaluating for investment, funding for co-investment, and access to the Israeli market. Thalys will have the ability to negotiate exclusive rights with any and all of the incubated companies for the Chinese market.
For more information:
iCAN
israel-cannabis.com